Modern Imaging in Prostate Cancer: Do We Treat Patients, or Their Scans?

Autor: Mason, M. D., van der Kwast, T. H., Mottet, N., Oprea-Lager, D. E., Rouvière, O.

Publikováno v: European Urology, 81(4), 319-322. Elsevier
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Prostate Cancer Guidelines Panel 2022, ' Modern Imaging in Prostate Cancer : Do We Treat Patients, or Their Scans? ', European Urology, vol. 81, no. 4, pp. 319-322 . https://doi.org/10.1016/j.eururo.2022.01.002
European Urology, 81(4), 319-322

New imaging techniques are more sensitive in prostate cancer and reveal sites of disease that may never have been seen with conventional imaging, resulting in stage migration and potentially a change in the clinical management. Until long-term data p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e812eee3d090528adedc719bcb15c87
https://doi.org/10.1016/j.eururo.2022.01.002

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

What is an acceptable false negative rate in the detection of prostate cancer?

Autor: Verbeek, J. F., Roobol, Monique J., Bangma, C. H., Kirkels, W. J., Rietbergen, J. B.W., van der Cruijsen, I. W., Raaijmakers, R., de Vries, S. H., Roemeling, S., Gosselaar, C., Wolters, T., van den Bergh, R. C.N., van Leeuwen, P. J., Bul, M., Zhu, Y., van Vugt, H. A., Yurdakul, G., Boeken-Kruger, A., Wijburg, C., Forouzanfor, M., de Boer, M., Vis, A. N., Venderbos, L. D.F., Schröder, Fritz H., Postma, R., van der Kwast, T. H., Hoedemaeker, R., van Leenders, A. G.J.L.H., Blijenberg, B. G., van Schaik, R. H.N., de Koning, H. J., Heijnsdijk, E., van der Maas, P. J., Beemsterboer, P., Otto, S. J., Essink-Bot, M., Korfage, I., Alberts, A. R., Bokhorst, L. P., Drost, F. H., Osses, D. F., Salman, J., Boer, R., Wildhagen, M., Draisma, G., Merkelbach, W., Hoekstra, W., van den Berg, E., Smit, A.

Publikováno v: Translational Andrology and Urology, 7(1), 54. AME Publishing Company
Translational Andrology and Urology, 7(1), 54-60. AME Publishing Company
the ERSPC Rotterdam study group 2018, ' What is an acceptable false negative rate in the detection of prostate cancer? ', Translational Andrology and Urology, vol. 7, no. 1, pp. 54-60 . https://doi.org/10.21037/tau.2017.12.12
Translational Andrology and Urology
Translational andrology and urology, 7(1), 54-60. AME PUBL CO

Background: In prostate cancer (PCa) screening men and their physicians aim to rule out the presence of potentially life threatening PCa. To date, prostate specific antigen (PSA) testing and systematic prostate biopsy (Bx)-in case of an elevated PSA-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044015e4c86e69dfc3c456d20673d460
https://dspace.library.uu.nl/handle/1874/364722

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy.

Autor: Hoedemaeker, R. F.¹, Van Der Kwast, T. H.¹, Schröder, F. H.¹

Publikováno v: BJU International. Dec2003 Supplement 2, Vol. 92, p92-96. 5p.